These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
223 related items for PubMed ID: 19891348
1. [Neurodegeneration and neuroprotection in multiple sclerosis]. Davydovskaia MV, Boĭko AN, Gusev EI. Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348 [Abstract] [Full Text] [Related]
2. Neurodegeneration and neuroprotective agents in multiple sclerosis. Fong JS, Rae-Grant A, Huang D. Recent Pat CNS Drug Discov; 2008 Nov; 3(3):153-65. PubMed ID: 18991805 [Abstract] [Full Text] [Related]
3. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T, Yong VW. J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747 [Abstract] [Full Text] [Related]
4. MS as a gateway disease. Lublin FD. J Neurol Sci; 2013 Oct 15; 333(1-2):73-5. PubMed ID: 23578792 [Abstract] [Full Text] [Related]
6. Immune-mediated neurodegeneration and neuroprotection in MS. Giuliani F, Yong VW. Int MS J; 2003 Dec 15; 10(4):122-30. PubMed ID: 14977489 [Abstract] [Full Text] [Related]
7. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Zivadinov R. Neurology; 2007 May 29; 68(22 Suppl 3):S72-82; discussion S91-6. PubMed ID: 17548573 [Abstract] [Full Text] [Related]
8. [Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review]. Shmidt TE. Zh Nevrol Psikhiatr Im S S Korsakova; 2012 May 29; 112(9 Pt 2):123-8. PubMed ID: 23378992 [Abstract] [Full Text] [Related]
9. Linkage between immunomodulation, neuroprotection and neurogenesis. Aharoni R, Arnon R. Drug News Perspect; 2009 May 29; 22(6):301-12. PubMed ID: 19771319 [Abstract] [Full Text] [Related]
10. The prospects for neuroprotection in MS. Hohlfeld R. Int MS J; 2003 Dec 29; 10(4):103-5. PubMed ID: 14977485 [Abstract] [Full Text] [Related]
11. Advancing therapeutic options in multiple sclerosis with neuroprotective properties. Stroet A, Linker RA, Gold R. J Neural Transm (Vienna); 2013 Sep 29; 120 Suppl 1():S49-53. PubMed ID: 23720188 [Abstract] [Full Text] [Related]
12. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, Tribolo A, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P. J Neuropathol Exp Neurol; 2009 May 29; 68(5):489-502. PubMed ID: 19525897 [Abstract] [Full Text] [Related]
13. Neuroprotection in multiple sclerosis: a therapeutic approach. Maghzi AH, Minagar A, Waubant E. CNS Drugs; 2013 Oct 29; 27(10):799-815. PubMed ID: 23955320 [Abstract] [Full Text] [Related]
14. Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. Bar-Or A, Rieckmann P, Traboulsee A, Yong VW. CNS Drugs; 2011 Sep 01; 25(9):783-99. PubMed ID: 21870889 [Abstract] [Full Text] [Related]